A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations
A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations
Sponsor: Kinnate Biopharma
Terminated
Due to a change in the Sponsor's corporate strategy the study was terminated early by the Sponsor prior to enrollment into the dose expansion part of the study (Part B).
Other Intrahepatic Cholangiocarcinoma trials with similar outcome
A PHASE1 clinical study on Intrahepatic Cholangiocarcinoma and Solid Tumor, Adult, this trial is terminated or withdrawn. The trial is conducted by Kinnate Biopharma and has accumulated 18 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
18 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1
-
Jun 2025 — Sep 2025 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Jun 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
▶ Show 13 earlier versions
-
Jan 2024 — May 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Jan 2024 [monthly]
Recruiting PHASE1
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE1
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE1
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Feb 2023 — Mar 2023 [monthly]
Recruiting PHASE1
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE1
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Kinnate Biopharma
For direct contact, visit the study record on ClinicalTrials.gov .